High materiality9/10
Pharvaris price target raised to $65 from $50 at Leerink Partners
Why it may matterVerify against the original reporting
Upside momentum intact; target implies strong potential.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
PHVS received an analyst target update from Leerink Partners.
- Leerink raises PHVS target to $65; current price $37.62.
Key facts
- 01
Target: $65
- 02
Posted price: $37.62
- 03
Analyst firm: Leerink Partners
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.